Chris Meekins, FBR research analyst, discusses three reasons to ignore Donald Trump's comments against the current drug prices.
Kenneth Frazier, the CEO of pharmaceutical giant Merck, says Trump's call to revamp Obamacare could prove useful.
CNBC’s Meg Tirrell talks to Kenneth Frazier, Merck CEO, at the fifth annual Forbes Healthcare Summit in New York about the future of drug pricing under the Trump administration as well as Alzheimer’s research.
Ravi Mehrotra, MTS Partners, and CNBC's Meg Tirrell discuss the high cost of pharmaceuticals in America and what can be done to rein prices in.
CNBC's Meg Tirrell speaks with Alkermes Chairman & CEO Richard Pops at the Partnering for Cures conference about drug pricing, his company's new depression drug and the opioid epidemic.
A study comparing three popular arthritis drugs shows they're all about equally safe and equally dangerous for the heart, reports NBC.
CNBC's Meg Tirrell reports the latest surrounding California's Proposition 61.
Bill George, Harvard Business School Professor and former Medtronic Chairman and CEO, and David Maris, Wells Fargo Securities Specialty Pharmaceutical Analyst, weigh in on the ongoing drug-pricing war.
CNBC's Meg Tirrell discusses the timeline on the war on drug pricing.
CNBC's Dominic Chu reports on possible charges being filed by the Justice Department against some generic drugmakers, according to Bloomberg.
Earnings are out for Gilead. CNBC's Meg Tirrell reports the details. “Fast Money” trader Jon Najarian weighs in.
Debating whether California voters should pass Proposition 61, the Drug Price Relief Act, with Scott Gottlieb, physician and American Enterprise Institute Resident Fellow, and Zeke Emanuel, University of Pennsylvania vice provost for global initiatives.
Jim Cramer addressed the stunning decline in McKesson, and got to the bottom of what triggered the sudden fall in the stock.
CNBC's Meg Tirrell reports the latest surrounding Ariad Pharmaceuticals and the company's drug price hike.
CNBC's Meg Tirrell reports the latest on a tweet sent by Sen. Bernie Sanders about Ariad Pharmaceuticals' cancer drug pricing.
Walgreens Boots Alliance reported a jump in quarterly profit and said it now expected its acquisition of Rite Aid Corp to close in early 2017.
Democratic vice presidential candidate Tim Kaine discusses Donald Trump's tax plan and Hillary Clinton's Catholic comments in the Wikileaks emails.
Democratic vice presidential candidate Tim Kaine discusses lowering drug prices, Wall Street and regulation and estate taxes.
CNBC's Meg Tirrell reports the latest on the controversy surrounding the California Drug Price Relief Act including the Bernie Sanders' support for the proposition.
Dr. Peter Bach, Memorial Sloan Kettering physician, discusses how copay assistance programs are actually causing drug prices to rise.